Cargando…

Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19

Hydroxychloroquine (HCQ), also known by its trade name Plaquenil®, has been used for over 50 years as a treatment for malaria, systemic lupus erythematosus, and rheumatoid arthritis. As the COVID-19 pandemic emerged in the United States and globally in early 2020, HCQ began to garner attention as a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhanel, George G., Zhanel, Michael A., Boreskie, Kevin F., Lynch, Joseph P., Karlowsky, James A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455223/ https://www.ncbi.nlm.nih.gov/pubmed/34557260 http://dx.doi.org/10.1155/2021/5942366

Ejemplares similares

Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli
por: Zhanel, George G., et al.
Publicado: (2018)

Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada
por: Zhanel, George G., et al.
Publicado: (2018)

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections
por: Zhanel, George G., et al.
Publicado: (2020)

Kisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity
por: Zhanel, George G., et al.
Publicado: (2016)

Microbiology and Preclinical Review of Omadacycline
por: Karlowsky, James A, et al.
Publicado: (2019)

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
por: Zhanel, George G, et al.
Publicado: (2015)

Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis
por: Zhanel, George G., et al.
Publicado: (2016)

708. In Vitro Activity of Plazomicin vs. Clinical Isolates of Gram-Negative Bacilli, Including Aminoglycoside Nonsusceptible and Multidrug-Resistant Subsets, Recovered from Patients Across Canada as Part of the CANWARD study, 2011–2018
por: Walkty, Andrew, et al.
Publicado: (2019)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 Stenotrophomonas maltophilia Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011–2016)
por: Walkty, Andrew, et al.
Publicado: (2017)

128. Adequacy of Commonly Prescribed Antimicrobials for Empiric Coverage of Gram-Negative Bacterial Pathogens Recovered from the Bloodstream of Patients Attending Emergency Rooms in Canada: Analysis of Data from the CANWARD Study, 2007 to 2018
por: Walkty, Andrew, et al.
Publicado: (2019)

Antimicrobial resistance patterns of bacterial pathogens recovered from the urine of patients at Canadian hospitals from 2009 to 2020
por: Walkty, Andrew, et al.
Publicado: (2022)

In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
por: Walkty, Andrew, et al.
Publicado: (2017)

254 In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 Pseudomonas aeruginosa Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013
por: Walkty, Andrew, et al.
Publicado: (2014)

2383. In Vitro Activity of Ceftolozane–Tazobactam in Comparison With Ceftazidime–Avibactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007–2017
por: Walkty, Andrew, et al.
Publicado: (2018)

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019
por: Karlowsky, James A., et al.
Publicado: (2022)

1216. Presence of the Narrow-Spectrum OXA-1 Beta-lactamase Enzyme Is Associated with Elevated Piperacillin-Tazobactam MIC Values Among ESBL-producing Escherichia coli Clinical Isolates (CANWARD, 2007-2018)
por: Walkty, Andrew, et al.
Publicado: (2021)

668. Presence of the Narrow-Spectrum OXA-1 Beta-Lactamase Enzyme is not Associated with Elevated Ceftolozane-Tazobactam MIC Values among ESBL-Producing Escherichia coli Clinical Isolates (CANWARD, 2011-2018)
por: Walkty, Andrew, et al.
Publicado: (2022)

Analyzing game statistics and career trajectories of female elite junior tennis players: A machine learning approach
por: Bozděch, Michal, et al.
Publicado: (2023)

Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19
por: Golden, Alyssa R., et al.
Publicado: (2022)

Age is just a number – and so is frailty: Strategies to inform resource allocation during the COVID-19 pandemic
por: Boreskie, Kevin F., et al.
Publicado: (2020)

Guanidylation and Tail Effects in Cationic Antimicrobial Lipopeptoids
por: Findlay, Brandon, et al.
Publicado: (2012)

Biocide Selective TolC-Independent Efflux Pumps in Enterobacteriaceae
por: Slipski, Carmine J., et al.
Publicado: (2017)

Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris
por: Zhanel, George, et al.
Publicado: (2018)

Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia
por: Zhanel, George G, et al.
Publicado: (2006)

Preventing Frailty Progression During the Covid-19 Pandemic
por: Boreskie, Kevin F., et al.
Publicado: (2020)

Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
por: Noreddin, Ayman M, et al.
Publicado: (2011)

No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19
por: Sands, Kenneth, et al.
Publicado: (2021)

Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant Pseudomonas aeruginosa
por: Yang, Xuan, et al.
Publicado: (2018)

Synthesis and Antibacterial Activities of Amphiphilic Neomycin B-based Bilipid Conjugates and Fluorinated Neomycin B-based Lipids
por: Bera, Smritilekha, et al.
Publicado: (2012)

Guanidinylated Polymyxins as Outer Membrane Permeabilizers Capable of Potentiating Rifampicin, Erythromycin, Ceftazidime and Aztreonam against Gram-Negative Bacteria
por: Ramirez, Danzel Marie, et al.
Publicado: (2022)

The Relative Age Effect at the Ice Hockey World Championships (IHWC) in the Years 2015–2017
por: Nykodým, Jiří, et al.
Publicado: (2020)

The relative age effect in top 100 elite female tennis players in 2007–2016
por: Zháněl, Jiří, et al.
Publicado: (2022)

Risks of hydroxychloroquine use for COVID-19 prophylaxis
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19
por: Sun, Xiaoxuan, et al.
Publicado: (2020)

Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019
por: Mandell, Lionel A, et al.
Publicado: (2022)

Risks of chloroquine or hydroxychloroquine use for COVID-19
Publicado: (2020)

Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19
por: Lei, Zi-Ning, et al.
Publicado: (2020)

Can we use hydroxychloroquine to treat COVID-19 now?
por: Chen, Jun, et al.
Publicado: (2021)

Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection
por: Bajpai, Jyoti, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t48lcvu975vi6j8kvo804sfh86